🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. ARD-101

    Ark Therapeutics

    Prader-Willi Syndrome

    phase 2 small molecule completed

    1 trial

  2. ARD-101

    Ark Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  3. ARD-101

    Ark Therapeutics

    Bariatric Surgery

    phase 2 small molecule completed

    1 trial

  4. ARGX-117, ARGX-113

    argenx

    AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

    phase 2 small molecule active

    1 trial

  5. ARI-0001, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    Disc Medicine

    relapsed/refractory Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  6. ARICEPT 10mg comprimidos recubiertos con película

    The George Institute

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  7. ARK-E021 5%

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  8. ARO-AAT

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  9. ARO-C3

    Arrowhead Pharmaceuticals Ireland Limited

    complement-mediated renal disease

    phase 2 small molecule active

    1 trial

  10. ARO-DM1 Intravenous (IV) Infusion

    Arrowhead Pharmaceuticals Ireland Limited

    Myotonic Dystrophy 1

    phase 2 small molecule active

    1 trial

  11. ARQ-151 cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis (Eczema)

    phase 2 small molecule completed

    1 trial

  12. ARQ-151 cream 0.3%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    2 trials

  13. ARQ-151 cream 0.5%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    1 trial

  14. ARQ-154

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 2 small molecule completed

    1 trial

  15. ARS-1

    Ars Pharmaceuticals Irl Limited

    Urticaria

    phase 2 small molecule completed

    1 trial

  16. ARS-1

    Ars Pharmaceuticals Irl Limited

    Asthma

    phase 2 small molecule completed

    1 trial

  17. ART0380, ART0380, GEMCITABINE , ART0380, IRINOTECAN , ART0380

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Solid Tumours

    phase 2 small molecule active

    1 trial

  18. ART27.13, Placebo, ART27.13

    ARTELO BIOSCIENCES, INC.

    Cancer Anorexia

    phase 2 small molecule active

    1 trial

  19. ARTEGENE

    Pari Pharma GmbH

    Severe Combined Immuno-Deficiency (SCID) caused by biallelic mutations in the Artemis gene (DCLRE1C)

    phase 2 small molecule active

    1 trial

  20. AS01 adjuvant (0.5 mL intramuscular)

    Hospital Authority, Hong Kong

    Immune System Responses and Trained Immunity After AS01 Administration

    phase 2 mab active

    1 trial

  21. ASCIMINIB, ASCIMINIB HYDROCHLORIDE, Asciminib

    Novartis Pharmaceuticals

    Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors

    phase 2 small molecule active

    1 trial

  22. ASLAN001

    Hospital Authority, Hong Kong

    Advanced/ Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  23. ASP1570, ASP1570, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Astellas Pharma GmbH

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  24. ASP2957

    Astellas Pharma GmbH

    X-linked myotubular myopathy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources